An interventional study of ISBCS and DSBCS in Bilateral Cataract, sponsored by Sloan W. Rush, MD. Completed at 1 site in United States. Open to participants aged 30 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-04-28.
Sponsored by Sloan W. Rush, MD · Not applicable, Interventional, and Treatment
To evaluate the safety and efficacy of treating visually significant bilateral cataract with the newer technique of Immediate Simultaneous Bilateral Cataract Surgery (ISBCS) versus the conventional technique of Delayed Sequential Bilateral Cataract Surgery (DSBCS) in a select patient population.
1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.
This study's enrollment of 100 is above the median of 79 across 1,092 interventional studies indexed under Cataract.
Browse Cataract studies →Sloan W. Rush, MD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Immediate Simultaneous Bilateral Cataract Surgery
Procedure: ISBCS
Delayed Sequential Bilateral Cataract Surgery
Procedure: DSBCS
same-day cataract surgery
bilateral surgery delayed by 1-3 weeks amongst eyes
Visual acuity
Best uncorrected and best spectacle corrected post-operative visual acuity
Time frame: 3 weeks
Recovery time and number of post-operative visits
Time frame: 6 months
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sloan W. Rush, MD